Junjiang Fu

Prof. Junjiang Fu

orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 June 2014 in Tumor Biology
Verified
Journal Article
Closed access
PDF file
MTMousumi Tania
Mousumi Tania
MKMd. Asaduzzaman Khan
Md. Asaduzzaman Khan
JFJunjiang Fu
Junjiang Fu

18 April 2017 in Oncotarget
Verified
Journal Article
Open access
PDF file
MKMd. Asaduzzaman Khan
Md. Asaduzzaman Khan
MTMousumi Tania
Mousumi Tania
SFShangyi Fu
Shangyi Fu
JFJunjiang Fu
Junjiang Fu
Https://doi.org/10.18632/oncotarget.17206 Md. Asaduzzaman Khan, Mousumi Tania, Shangyi Fu, Junjiang Fu

20 July 2013 in Tumor Biology
Verified
Journal Article
Closed access
PDF file
MKMd. Asaduzzaman Khan
Md. Asaduzzaman Khan
HCHan-Chun Chen
Han-Chun Chen
DZDianzheng Zhang
Dianzheng Zhang
JFJunjiang Fu
Junjiang Fu

14 May 2020 in Molecular Biology Reports
Verified
Journal Article
Closed access
PDF file
JFJiewen Fu
Jiewen Fu
BZBaixu Zhou
Baixu Zhou
LZLianmei Zhang
Lianmei Zhang
KBKyathegowdanadoddi Srinivasa Balaji
Kyathegowdanadoddi Srinivasa Balaji
CWChunli Wei
Chunli Wei
JFJunjiang Fu
Junjiang Fu

1 October 2013 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
LZLing Zhao
Ling Zhao
YWYumeng Wei
Yumeng Wei
JFJunjiang Fu
Junjiang Fu
YHYu Huang
Yu Huang
BHBing He
Bing He
YZYang Zhou
Yang Zhou
Baicalin is one of the main bioactive flavone glucuronides derived as a medicinal herb from the dried roots of Scutellaria baicalensis Georgi, and it is widely used for the treatment of fever, inflammation, and other conditions. Due to baicalin's poor solubility in water, its absolute bioavailability after oral administration is only 2.2%. The objective of this study was to develop a novel baicalin-loaded nanoemulsion to improve the oral bioavailability of baicalin. Based on the result of pseudoternary phase diagram, the nanoemulsion formulation consisting of soy-lecithin, tween-80, polyethylene glycol 400, isopropyl myristate, and water (1:2:1.5:3.75:8.25, w/w) was selected for further study. Baicalin-loaded nanoemulsions (BAN-1 and BAN-2) were prepared by internal or external drug addition and in vivo and in vitro evaluations were performed. The results showed that the mean droplet size, polydispersity index, and drug content of BAN-1 and BAN-2 were 91.2 ± 2.36 nm and 89.7 ± 3.05 nm, 0.313 ± 0.002 and 0.265 ± 0.001, and 98.56% ± 0.79% and 99.40% ± 0.51%, respectively. Transmission electron microscopy revealed spherical globules and confirmed droplet size analysis. After dilution 30-fold with water, the solubilization capacity of BAN-1 and BAN-2 did not change. In vitro release results showed sustained-release characteristics. BAN-1 formulation was stable for at least 6 months and was more stable than BAN-2. In rats, the area under the plasma drug concentration-time curve value of BAN-1 was 1.8-fold and 7-fold greater than those of BAN-2 and free baicalin suspension after oral administration at a dose of 100 mg/kg. In conclusion, these results demonstrated that the baicalin-loaded nanoemulsion formulation, in particular BAN-1, was very effective for improving the oral bioavailability of baicalin and exhibited great potential for future clinical application.

26 September 2023 in Cancers
Verified
Journal Article
Open access
PDF file
JFJunjiang Fu
Junjiang Fu
PIProf. Saber Imani
Prof. Saber Imani
MWMei-Yi Wu
Mei-Yi Wu
RWRay-Chang Wu
Ray-Chang Wu
MicroRNA (miRNA) are small noncoding RNAs that play vital roles in post-transcriptional gene regulation by inhibiting mRNA translation or promoting mRNA degradation. The dysregulation of miRNA has been implicated in numerous human diseases, including cancers. miR-34 family members (miR-34s), including miR-34a, miR-34b, and miR-34c, have emerged as the most extensively studied tumor-suppressive miRNAs. In this comprehensive review, we aim to provide an overview of the major signaling pathways and gene networks regulated by miR-34s in various cancers and highlight the critical tumor suppressor role of miR-34s. Furthermore, we will discuss the potential of using miR-34 mimics as a novel therapeutic approach against cancer, while also addressing the challenges associated with their development and delivery. It is anticipated that gaining a deeper understanding of the functions and mechanisms of miR-34s in cancer will greatly contribute to the development of effective miR-34-based cancer therapeutics.